spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Nippon Kayaku 

 HSMN NewsFeed - 4 Mar 2016
Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat(R) Against Nippon Kayaku Co., Ltd.
Biopharmaceuticals Generics Oncology Litigation
 HSMN NewsFeed - 9 Nov 2015
Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin(TM) (ubenimex) for Inflammatory Diseases Involving LTB4
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Jul 2013
Merit Medical Announces Multiple Regulatory Approvals
Devices Interventional FDA Regulatory
 HSMN NewsFeed - 7 Oct 2009
Study Shows Uterine Artery Embolization Compares Favorably to Laparoscopic Bilateral Occlusion for Treating Uterine Fibroids
Devices Interventional
 HSMN NewsFeed - 17 Aug 2009
BioSphere Medical Announces New Journal Articles Published Discussing Uterine Fibroid Embolization
Devices
 HSMN NewsFeed - 16 Apr 2009
BioSphere Medical Enters into Exclusive Distribution Agreement with Nippon Kayaku for Japanese Market
Devices Distribution
 HSMN NewsFeed - 1 Oct 2008
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2008
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 11 Apr 2008
Amrubicin is Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Mar 2008
Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2007
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Urology
 HSMN NewsFeed - 19 Mar 2007
Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of In-House Urology Expert Bela S. Denes, MD, FACS
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 25 Jan 2007
Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Jan 2007
Spectrum Pharmaceuticals Announces FDA's Acceptance of Ozarelix IND and Approval of Phase 2b Protocol in BPH (Benign Prostate Hypertrophy)
Biopharmaceuticals Urology
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 3 Oct 2006
Spectrum Pharmaceuticals Announces Positive Phase 2 Data with Ozarelix in Patients with Benign Prostatic Hypertrophy
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Oct 2006
AEterna Zentaris Announces Positive Phase 2 Results for Ozarelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Aug 2006
AEterna Zentaris Enters a License and Collaboration Agreement for Ozarelix with Nippon Kayaku for the Japanese Market
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Jun 2006
AEterna Zentaris Receives Green Light from FDA to Move Forward into Phase 3 Program with Cetrorelix in BPH
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 20 Apr 2006
AEterna Zentaris Gains Market Approval for Cetrotide(R) (cetrorelix) in Japan for In Vitro Fertilization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jan 2006
AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for Cetrorelix in Benign Prostate Hyperplasia
Biopharmaceuticals Urology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Nippon Kayaku
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.